Sort
4,870 grants matching “glp 1”
Clinical Trials and Ancillary Assays
$874,348Harriet L Robinson · Geovax, Inc. · U19 · FY2011 · AI
Safety and Toxicology Studies of CLT-005 as a Therapeutic for Diabetic Macular Ed
$873,711Rafal A Farjo · Charlesson, Llp · R44 · FY2012 · EY
Therapeutic Thrombin Analogs
$872,549Erik Ian Tucker · Aronora, Inc. · R44 · FY2016 · HL
Drugs Targeting Dormant Tumors as Anti-Metastatic Agents
$871,678Michael A Ihnat · Dormatarg, Inc. · R44 · FY2012 · CA
Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis
$871,604Athan Kuliopulos · Oasis Pharmaceuticals · R42 · FY2014 · DK
Development of PAR2 Inhibitors for the Treatment of Nonalcoholic steatohepatitis
$871,014Athan Kuliopulos · Oasis Pharmaceuticals · R42 · FY2015 · DK
Advanced Nitric Oxide Release Bactericidal Urinary Catheters
$869,729Hao Chen · Biocrede, Inc. · R42 · FY2015 · DK
NP855 for Targeting Thyrointegrin αvβ3 receptors and Norepinephrine Transporter in Neuroblastoma Management
$869,433Paul Davis · Nanopharmaceuticals, Llc · R44 · FY2025 · CA
Development of a novel small molecule RPN13 inhibitor and therapeutic for advanced ovarian cancer patients
$868,417Ravi Kumar Anchoori · Up Therapeutics, Inc. · R44 · FY2023 · CA
Project 1 - Profectus Biosciences, Inc.
$867,787John H Eldridge · Henry M. Jackson Fdn For The Adv Mil/Med · U19 · FY2023 · AI
Retinal Gene Therapy
$867,558Zhijian Wu · National Eye Institute · ZIA · FY2013 · EY
Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome
$866,989Charles Testa · Curza Inc · R01 · FY2017 · AI
Development of Estrogen Receptor B Selective Receptor Agonists to Treat Neuropath
$866,941Ethan Samuel Burstein · Acadia Pharmaceuticals, Inc. · U44 · FY2014 · NS
Early Screening of Breast Lesion Trial (Phase III Pivotal)
$866,065David A. Benaron · Spectros Corporation · R44 · FY2008 · CA
Tethosomes: a non-viral DNA platform for durable expression of therapeutic transgenes in specific target cells
$865,162Benjamin Richard Hawley · Engage Biologics Inc. · R44 · FY2025 · TR
Project 1 - Profectus Biosciences, Inc.
$864,462John H Eldridge · Henry M. Jackson Fdn For The Adv Mil/Med · U19 · FY2021 · AI
Translational Research for Retinal Degeneration Therapies
$864,255Gustavo David Aguirre · University Of Pennsylvania · R01 · FY2010 · EY
Clinical Development of Elafin as a PAH Therapy
$864,097Roham Zamanian · Stanford University · P01 · FY2018 · HL
Development of an antibody-oligonucleotide conjugate for treatment of Head and Neck Squamous Cell Carcinoma
$863,708Anthony D Saleh · Mirecule, Inc. · R44 · FY2024 · CA
Development of Novel Melanocortin-4 Receptor Peptide Agonists for the Treatment ofMC4R Haploinsufficiency
$862,674Tomi K Sawyer · Courage Therapeutics, Inc. · R42 · FY2023 · DK
Combination Therapy with Semaglutide and Anti-Amyloid Antibodies for Alzheimers Disease
$859,410Cynthia A Lemere · Brigham And Women'S Hospital · R01 · FY2024 · AG
Efficacy and Safety of an Aerosolized Recombinant Butyrylcholinesterase Pretreatm
$858,920Yvonne J Rosenberg · Plantvax, Inc. · R44 · FY2014 · NS
Rho GTPase inhibitor for refrigerated platelet storage
$858,735Brittany De Kouchkovsky · Ogb4 Inc · R44 · FY2023 · HL
A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens
$858,436Paul Sebahar · Curza Inc · R44 · FY2025 · AI
IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis
$858,320Dominick Auci · Therapyx, Inc. · R44 · FY2020 · DK